NCT07213349 - Daridorexant for Alzheimer Disease Prevention | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Alzheimer Disease (AD)

Interventions

DRUG

Daridorexant 50 mg

Study drug (Daridorexant 50 mg) taken orally each night 30 minutes before bedtime, for the 1 year duration of the study

DRUG

Placebo

Study drug (Placebo) will be taken orally each night, 30 minutes before bedtime, for the 1 year duration of the study

Trial Locations (1)

Centre StoP-Alzheimer (Douglas Mental Health University Institute - Research Centre), Montreal

All Listed Sponsors

collaborator

Weston Family Foundation

OTHER

lead

Douglas Mental Health University Institute

OTHER